Daniel J Crona
Overview
Explore the profile of Daniel J Crona including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
497
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kim S, Szeto A, Morgan K, Brower B, Dunn M, Khandani A, et al.
PLoS One
. 2021 Dec;
16(12):e0262326.
PMID: 34972194
[This corrects the article DOI: 10.1371/journal.pone.0253021.].
12.
Quintanilha J, Racioppi A, Wang J, Etheridge A, Denning S, Pena C, et al.
Pharmacogenomics J
. 2021 Dec;
22(2):145.
PMID: 34934177
No abstract available.
13.
Quintanilha J, Racioppi A, Wang J, Etheridge A, Denning S, Pena C, et al.
Pharmacogenomics J
. 2021 Nov;
22(1):82-88.
PMID: 34775477
No biomarkers are available to predict patients at risk of developing hypertension induced by VEGF-pathway inhibitors. This study aimed to identify predictive biomarkers of hypertension induced by these drugs using...
14.
Dennison T, Heiling H, Deal A, Brunk K, Kemper R, Crona D, et al.
J Oncol Pharm Pract
. 2021 Nov;
29(1):96-104.
PMID: 34751060
Introduction: Palbociclib is a small-molecule cyclin-dependent kinase 4/6 inhibitor used to treat hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Patient-specific factors impacting dose reductions or discontinuations...
15.
Zhu J, Rao G, Armistead P, Ptachcinski J, Weiner D, Wiltshire T, et al.
Clin Transl Sci
. 2021 Nov;
15(3):583-587.
PMID: 34743423
No abstract available.
16.
Kalogirou A, East M, Laitinen T, Torrice C, Maffuid K, Drewry D, et al.
Molecules
. 2021 Oct;
26(19).
PMID: 34641454
A focused series of substituted 4-1,2,6-thiadiazin-4-ones was designed and synthesized to probe the anti-cancer properties of this scaffold. Insights from previous kinase inhibitor programs were used to carefully select several...
17.
Szeto A, Bucci T, Deal A, Zhu A, Ahmad M, Cass A, et al.
Ann Pharmacother
. 2021 Sep;
56(7):753-763.
PMID: 34541881
Background: Tyrosine kinase inhibitors (TKIs) are the front-line therapy for chronic myeloid leukemia (CML), where phase 3 clinical trials have demonstrated their safety and efficacy. However, trial patients may not...
18.
Zhu J, Wu Y, Beechinor R, Kemper R, Bukkems L, Mathot R, et al.
Haemophilia
. 2021 Aug;
27(6):974-983.
PMID: 34405493
Introduction: Haemophilia A patients require perioperative clotting factor replacement to limit excessive bleeding. Weight-based dosing of Factor VIII (FVIII) does not account for inter-individual pharmacokinetic (PK) variability, and may lead...
19.
Kim S, Szeto A, Morgan K, Brower B, Dunn M, Khandani A, et al.
PLoS One
. 2021 Jun;
16(6):e0253021.
PMID: 34153052
Introduction: Radium-223, abiraterone, and enzalutamide have each been shown to significantly improve survival as monotherapy in patients with metastatic castration-resistant prostate cancer. However, effects of combination radium-223 plus abiraterone or...
20.
Maffuid K, Koyioni M, Torrice C, Murphy W, Mewada H, Koutentis P, et al.
Bioorg Med Chem Lett
. 2021 May;
43:128078.
PMID: 33951490
Heteroatom rich 1,2,3-dithiazoles are relatively underexplored in medicinal chemistry. We now report screening data on a series of structurally diverse 1,2,3-dithiazoles and electronically related 1,2,4-dithiazines with the aim of identifying...